Open Access · CC BY 4.0
Patient‐derived xenografts: Practical considerations for preclinical drug testing
HemaSphere · 2025-04 · 9 (4)
DOI: 10.1002/hem3.70133 ↗Kurz gefasst
Fachartikel in der Zeitschrift HemaSphere, online erschienen am 16.04.2025. Verfasst von Charles E de Bock. Beteiligte Einrichtung: Lowy Cancer Research Centre, Children's Cancer Institute Randwick New South Wales Australia. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Lowy Cancer Research Centre, Children's Cancer Institute Randwick New South Wales Australia.
- Faculty of Medicine UNSW, School of Clinical Medicine Sydney New South Wales Australia.
ORCID-Profile: Charles E de Bock
Zitieren
APA
de Bock, C. E. (2025). Patient‐derived xenografts: Practical considerations for preclinical drug testing. HemaSphere, 9(4). https://doi.org/10.1002/hem3.70133
Vancouver
de Bock CE. Patient‐derived xenografts: Practical considerations for preclinical drug testing. HemaSphere. 2025;9(4). doi:10.1002/hem3.70133
BibTeX
@article{deBock2025,
author = {de Bock, Charles E},
title = {Patient‐derived xenografts: Practical considerations for preclinical drug testing},
journal = {HemaSphere},
year = {2025},
volume = {9},
number = {4},
doi = {10.1002/hem3.70133}
}
EUVIMED